Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • Statera Pharmaceuticals treatment for Covid-19 Long-Haulers
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    October 28, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…

    read more
    Jessica N. Abraham Comments Off on Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

    You May Also Like

    Green Policy, Generation Hemp, Melissa Pagen, Gary C Evans, Industrial Hemp Processor, Hemp Cleaning, Green Policy, ESG

    Generation Hemp’s Green Policy is Inspired by a Cause, Executives Move From Oil and Gas to Industrial Green

    August 30, 2021
    Cadiac heart monitoring

    Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis

    November 11, 2021
    ESG, Sustainability, Clean Tech, Clean Mining, GreenTech, Nouveau Monde Graphite, Battery Metals, Cobalt, Lithium, Graphite, Graphene, Benzinga, Nickel,

    The Catch 22 of ESG Funding and How A Company Is Setting Standards, Leading by Example

    October 12, 2021
  • Statera Biopharmaceuticals, Groundbreaking Biomedicine Treatment
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Statera BioPharma: The Ticker Formerly Known as CBLI

    September 7, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets.  This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases.  The company began trading as CLBI, last month,…

    read more
    Jessica N. Abraham Comments Off on Statera BioPharma: The Ticker Formerly Known as CBLI

    You May Also Like

    Hemp-based animal bedding for small animals and farms -- pest free, pesticide free, mold-free, antibacterial, safe, edible.

    Industrial Hemp: Big Win for Pet Stores, Farmers, and Animals

    October 25, 2021
    Generation Hemp, Industrial Hemp, Pet Bedding, Animal Bedding, Not Hay, Not Straw, Mold-Free, Pest-Free, Sustainable

    Rowdy Rooster Hemp Unleashed | Official Launch of Generation Hemp’s Animal Bedding Brand for Small Animals

    September 29, 2021
    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.